+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti Malarial Drugs Market - Growth, Trends, and Forecasts (2020-2025)

  • ID: 4896065
  • Report
  • May 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Alliance Pharma PLC
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals
  • MORE
The antimalarial drugs are used for the treatment and prevention of malaria infection. This market has been growing in recent years due to the high prevalence of malaria, especially in developing and underdeveloped countries. According to the “World Malaria Report 2018” by World Health Organization (WHO), there were an estimated 219 million cases and nearly 435,000 malaria-related deaths in 2017. Hence, the high prevalence of malaria is driving the growth of this market.

The other factors includes the increase in awareness initiatives by governments and research for new anti-malarial drugs and therapies are also helping this market grow. However, side-effects of anti-malarial drugs and presence of counterfeit and substandard drugs are restraining the overall growth of this market.

Key Market Trends

Artemisinin Compounds Segment is Expected to Register High Growth During the Forecast Period

The artemisinin-based compounds (ACTs) and the combination therapies (ACTs) for found to effective treatment being used for the treatment of uncomplicated malaria caused by the P. falciparum parasite. By combining 2 active ingredients with different mechanisms of action, ACTs are the most effective antimalarial medicines being currently available in the market.

According to the WHO Report, they currently recommend 5 ACTs for use against P. falciparum malaria. However, the increasing consumption of artemisinin based compounds and monotherapies will help the overall growth of the market.

Middle East and Africa Holds a Large Share of the Market Growth During the Forecast Period

Middle East and Africa has been accounted for the major market share and is expected to continue this trend, owing to rapid surge in prevalence of malaria in the region. According to the World Health Organization (WHO), there were an estimated 228 million cases of malaria worldwide in 2018, out of which WHO African Region carried a disproportionately high share of the global malaria burden. Therefgore the Middle East and Africa region is expected to have one of the largest share in the total anti-malarial drugs market.

On the other side, Asia-Pacific is also estimated to register the fastest growth due to the increase in awareness regarding the use of antimalarial drugs for early diagnosis of the infection for better treatment.

Competitive Landscape

Majority of the anti-malarial drug are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. These global players are mostly based in developed countries like United States, United Kingdom, France, Germany and Japan. Asia-pacific is also witnessing an emergence of some small players which has helped the market grow and increased the competitiveness.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alliance Pharma PLC
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Malaria in Developing and Under Developed Countries
4.2.2 Increasing Awareness Initiatives Undertaken by Government
4.2.3 Increasing Research for New Drugs and New Combinations Therapies
4.3 Market Restraints
4.3.1 Side Effects of Anti-malaria Drugs
4.3.2 Presence of Counterfeit and Substandard Antimalarial Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Aryl aminoalcohol compounds
5.1.2 Antifolate compounds
5.1.3 Artemisinin compounds
5.1.4 Other Drug Types
5.2 By Malaria Type
5.2.1 Plasmodium Falciparum
5.2.2 Plasmodium Vivax
5.2.3 Plasmodium Malariae
5.2.4 Plasmodium Ovale
5.3 By Mechanism of Action
5.3.1 Treatment for Malaria
5.3.2 Prevention from Malaria
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Mylan N.V.
6.1.2 Cipla Limited
6.1.3 GlaxoSmithKline Plc
6.1.4 Novartis AG
6.1.5 F. Hoffmann-La Roche AG
6.1.6 Bayer AG
6.1.7 Lincoln Pharmaceuticals
6.1.8 Strides Pharma Science Limited
6.1.9 Glenmark Pharmaceuticals
6.1.10 Alliance Pharma PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
  • Mylan N.V.
  • Cipla Limited
  • GlaxoSmithKline Plc
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Lincoln Pharmaceuticals
  • Strides Pharma Science Limited
  • Glenmark Pharmaceuticals
  • Alliance Pharma PLC
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll